Useful Articles

The NYSE Oscillator indicates the stock market is near or has reached an i

According to USFDA, a combination product is one composed of any combination of a drug and device; biological product and device; drug and biological product

ntermediate-term peak. The two charts below are same period weekly charts

; or drug, device, and biological product and fixed dose combination would include two or more combinations of drug.

Examples of combination products may in

of the NYSE Oscillator and SPX. There's generally a positive correlation b

lude drug-coated devices, drugs packaged with delivery devices in medical kits, and drugs and devices packaged separately but intended to be used together.

etween the Oscillator and SPX. Normally, when the Oscillator is around 50,

here is enormous increase in the number of combination products entering the market in the recent years. Combination products have proven advantages but fixe

SPX is near a short-term top, and when the Oscillator is around negative

d dose combinations are still in the process of convincing regulatory authority on their advantages over the single ingredient formulations.

Combination pro

50, SPX is near a short-term bottom.

Currently, the Oscillator's 10-week

ucts have become life saving products for the pharmaceutical companies who doesn’t have many innovative molecules in their product pipeline and have been inc

MA (blue line) is about 27, which is the third time over the past five yea

easingly used in the product life cycle management. Even the companies having product patents are trying to extend their product life cycle through the combi

rs it has risen above 25 (see orange arrows). Each time the Oscillator's 1

nation products and maximize the revenues. But the companies involved in this practice are overlooking that they are burdening the patients both economically

0-week MA has been above 25, SPX has pulled-back at least 5% within three

and physically. They need to rightly judge the benefits of the combination products and they have to even look at the risks involved when combining the produ

months (also shown in older charts). Moreover, each time the Oscillator's

ts. Some of the combination products were well accepted by physicians while others suffered. Companies involved in development of combination products are fi

0-week MA topped just below 25, SPX pulled-back at least 5% within three m

ding difficulty in defining their combination products and facing various challenges from selecting a combination to marketing it.

Following aspects would a

onths (see gray arrows).

SPX upper resistance is 1,315 (previous multi-ye

dd to the challenges in developing combination products:

Which markets to tap where the combination products can do fairly well?
Which combination prod

ar high). Another (lower) resistance level is just over 1,300 (current wee

cts are meaningful and rational?
Which therapeutic categories to select?
Which Combinations can address unmet needs of the patients?
Do combin

kly upper Bollinger Band). Short-term major support is 1,275 (prior high),

tions increase the patient compliance?
What would be the developing cost?
How to tackle the risks encountered during combination product developmen

and intermediate-term major support is 1,246 (also, a prior high). SPX ha

t?

As combination products don't fit into the traditional categories of drugs, medical devices, or biological products, the USFDA is in the process of devel

s become less volatile over the cyclical bull market. Consequently, there

ping new procedures for reviewing their safety, efficacy and quality.

Professional from academic institutions, pharmaceutical industries, health care indust

hasn't been a 10% correction throughout the three-year bull market. 10% co

y and representatives from various regulatory agencies are working out to design the regulatory requirements for manufacture and sale of combination products

rrections take place every 1 1/2 years on average. Therefore, the risk tha

.

As there is an increasing trend of the combination products companies manufacturing such products should be able to tackle the problems involved in the de

t the next pullback will be greater is high. A 10% fall from 1,300 is 1,17

elopment. They need to be wiser in analyzing the market trends and the regulatory requirements.

Companies that provide selfless information through particip

0.

Charts available at PeakTrader.com Forum Index Market Overview section

tion in industry events and feedback to regulatory authorities would be able to face the challenges and will be successful in developing combination products

HTTP = HTML link (for blogs, profiles,phorums):
<a href="http://www.usefularticles.org.ua/article/117667/usefularticles-SPX-IntermediateTerm-Peak.html">SPX Intermediate-Term Peak</a>

BB link (for phorums):
[url=http://www.usefularticles.org.ua/article/117667/usefularticles-SPX-IntermediateTerm-Peak.html]SPX Intermediate-Term Peak[/url]

Why, with all our technological and medical improvements, have we still not found a way to promote production without the use of competition. Why, even in some of more humanitarian causes, do we still bow down to the higher executive, struggle for the higher paycheck, work harder for the privelege of funding someone elses house or boat? There was a time when humanity didn't do this, can this wisdom not be shared by the business world as well?

So you're a beginner, and you just build your first squeeze page, and you are collecting these opt in e-mail addresses. Now, what next?

One of the most common questions asked on forums and discussion lists concerning Google Adwords is should content network be turned on or left off? Here is what has worked well for me and others.

Tags

Links

Useful Articles - SPX Intermediate-Term Peak

Related Articles: